RXL:NYE-ProShares Ultra Health Care (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 110.189

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.54K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

ETFs Containing RXL

KGHG 4.13 % 0.00 %

N/A

N/A
EUSC WisdomTree Europe Hedged .. 2.46 % 0.58 %

N/A

USD 0.05B
ASWA:XETRA European Green Deal UCITS.. 2.35 % 0.00 %

N/A

USD 0.02B
VXM:CA First Asset Morningstar I.. 0.56 % 0.70 %

N/A

CAD 0.01B
IEUS iShares MSCI Europe Small.. 0.00 % 0.40 %

N/A

USD 0.10B
VXM-B:CA CI Morningstar Internatio.. 0.00 % 0.00 %

N/A

CAD 0.29B
SCZ iShares MSCI EAFE Small-C.. 0.00 % 0.39 %

N/A

USD 9.11B
LGWU:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A
ZPRX:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.25B
ZPRX:XETRA SPDR® MSCI Europe Small .. 0.00 % 0.00 %

N/A

USD 0.17B
1388:TSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -84.93% 20% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.93% 20% F 5% F
Trailing 12 Months  
Capital Gain -83.10% 12% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.10% 12% F 5% F
Trailing 5 Years  
Capital Gain -72.87% 26% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.87% 26% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 14.23% 36% F 76% C+
Dividend Return 14.45% 33% F 72% C
Total Return 0.22% 22% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 28.84% 96% N/A 36% F
Risk Adjusted Return 50.13% 79% B- 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.